JUNE 30, 2020, NEW YORK CITY — In molecular biology, chaperones are a class of proteins that help regulate how other proteins fold. Folding is an important step in the manufacturing process for proteins. When they don’t fold the way they’re supposed to, it can lead to the development of diseases such as cancer.
Researchers at the Sloan Kettering Institute have uncovered important findings about what causes chaperones to malfunction as well as a way to fix them when they go awry. The discovery points the way to a new approach for developing targeted drugs for cancer and other diseases, including Alzheimer’s disease.
“Our earlier work showed that defects in chaperones could lead to widespread changes in cells, but no one knew exactly how it happened,” says SKI scientist Gabriela Chiosis, senior author of a study published June 30 in Cell Reports. “This paper finally gets into the nuts and bolts of that biochemical mechanism. I think it’s a pretty big leap forward.”
How a “Good Guy” Turns Bad
The research focused on a chaperone called GRP94, which plays an important role in regulating how cells respond to stress. Stress in cells is a common sign of disease, especially those related to aging, such as cancer and Alzheimer’s. Dr. Chiosis has studied the role of chaperones and stress in both of these disorders for many years.
In the new study, Dr. Chiosis and her colleagues looked at changes in GRP94 in cancer cells, including cells from patients treated for breast cancer at Memorial Sloan Kettering. They found that when GRP94 undergoes a process called glycosylation, in which a sugar molecule is added, it completely changes the way that chaperone behaves.
“It goes from protein that was very floppy and flexible to one that’s very rigid,” explains Dr. Chiosis, a member of SKI’s Chemical Biology Program. “This one change is enough to convert it from a good guy in the cell to a bad guy. That, in turn, can make the cell behave in a way that’s not normal.”
When GRP94 undergoes this change, it moves to a different part of the cell. Normally, it’s found in the endoplasmic reticulum, where proteins are made and folded. But after the sugar is added, it moves to the part of the cell called the plasma membrane. This leads to widespread dysfunction of proteins and a more aggressive cancer.
Finding a Prototype for Future Drugs
The researchers report in the paper that they have already identified a small molecule that acts on GRP94 in the plasma membrane, called PU-WS13. This molecule appears to repair the defects in GRP94, allowing it to behave normally again.
“The changes that we saw only happen in diseased cells, such as cancer cells or those related to Alzheimer’s,” Dr. Chiosis says. “That makes them a good target for therapies because healthy cells are unlikely to be affected.”
But Dr. Chiosis explains that more research is needed before a new drug can be developed based on this approach. “PU-WS13 is just a prototype,” she says. “It has to be tailored for use in humans. We’re investigating how to make this into something that might work as a drug.”
This study was funded by the National Institutes of Health under grants R01 CA172546, R56 AG061869, R01 CA186866, P30 CA08748, and P50 CA192937; William H. Goodwin and Alice Goodwin and the Commonwealth Foundation for Cancer Research, through the Experimental Therapeutics Center of MSK; the Lymphoma Research Foundation; and the Steven A. Greenberg Charitable Trust.
Dr. Chiosis and several of her co-authors are inventors on patents covering PU-WS13 and related science. Dr. Chiosis is also a founder of Samus Therapeutics and a member of its board of directors.
About Memorial Sloan Kettering (MSK):
As the world’s oldest and largest private cancer center, Memorial Sloan Kettering has devoted more than 135 years to exceptional patient care, influential educational programs, and innovative research to discover more effective strategies to prevent, control and, ultimately, cure cancer. MSK is home to more than 20,000 physicians, scientists, nurses, and staff united by a relentless dedication to conquering cancer. Today, we are one of 51 National Cancer Institute-designated Comprehensive Cancer Centers, with state-of-the-art science and technology supporting groundbreaking clinical studies, personalized treatment, and compassionate care for our patients. We also train the next generation of clinical and scientific leaders in oncology through our continually evolving educational programs, here and around the world. Year after year, we are ranked among the top two cancer hospitals in the country, consistently recognized for our expertise in adult and pediatric oncology specialties. http://www.